TRIAL INTELLIGENCE REPORT: NCT06819007  
https://clinicaltrials.gov/study/NCT06819007
Trial Name: DESTINY-Ovarian01
Full Title: Trastuzumab Deruxtecan (T-DXd/ENHERTU) + Bevacizumab vs Bevacizumab MonotherapyPhase: 3 (Randomized, Open-Label)Sponsor: Daiichi SankyoStatus: âœ… RECRUITING (Started March 19, 2025)Enrollment: 582 patientsPrimary Completion: November 2028ClinicalTrials.gov Linkhttps://clinicaltrials.gov/study/NCT06819007
ðŸ”¥ WHY THIS MATTERS FOR AK - CRITICAL ANALYSIS
âœ… AK IS A STRONG MATCH:
1. DISEASE MATCH âœ… PERFECT
Requirement: Stage III/IV high-grade epithelial ovarian cancer
Ayesha: Stage IVB HGSOC âœ…
Match Score: 100%
2. TREATMENT LINE âœ… PERFECT
Requirement: First-line maintenance (after completing platinum + bevacizumab frontline)
Ayesha: Treatment-naive, will receive carboplatin + paclitaxel + bevacizumab (NCCN SOC)
Match Score: 100%
3. HER2 STATUS âš ï¸ CRITICAL GATE
Requirement: HER2 IHC 3+/2+/1+ (ANY expression by ASCO-CAP gastric scoring)
Ayesha: UNKNOWN - NO HER2 testing done yet (ASK your doctor about HER2 gene)
Action Required: Order HER2 IHC on her tumor biopsy IMMEDIATELY
4. BRCA STATUS âœ… PERFECT
Requirement: BRCA wildtype (BRCA-mutated patients EXCLUDED)
Ayesha: Germline BRCA1/2 NEGATIVE âœ…
Match Score: 100%
5. HRD STATUS âš ï¸ NEEDS TESTING
Requirement: Local HRD test result available
Ayesha: PENDING (MyChoice test ordered?) -> (CONFIRM on this with your doctor around HRD status)
Note: Trial accepts HRD-positive patients IF they have contraindication to PARP (see exclusion #426)
6. GEOGRAPHIC âœ… NYC LOCATION AVAILABLE
Trial Site: Mount Sinai (NYC) - 10029 zip code
Ayesha: NYC metro resident
Travel: < 30 minutes
Match Score: 100%
ðŸ§¬ CLINICAL MECHANISM - REVOLUTIONARY APPROACH
What T-DXd (Trastuzumab Deruxtecan) Is:
Drug Class: HER2-targeted antibody-drug conjugate (ADC)
Mechanism: "Trojan horse" approach
Trastuzumab (Herceptin) binds to HER2 on tumor cells
Delivers deruxtecan (topoisomerase I inhibitor payload)
Kills HER2+ cells AND nearby cells (bystander effect)
Why This Is Groundbreaking for Ovarian Cancer:
Low HER2 Expression Works: Unlike breast cancer (needs HER2 3+), this trial accepts IHC 1+ (low expression)
40-60% of ovarian cancers are HER2 1+/2+ (previously considered "HER2-negative")
Proven in Other Cancers: T-DXd FDA-approved for breast cancer, gastric cancer, lung cancer (NEJM data shows dramatic responses)
The "One-Two Punch" Strategy:
Bevacizumab (standard maintenance) â†’ Starve tumor blood supply
T-DXd (experimental arm) â†’ Direct tumor cell kill + bystander effect
Synergy: Anti-angiogenesis + chemotherapy payload = enhanced efficacy
ðŸ“Š ELIGIBILITY ASSESSMENT FOR AK
Criterion	Ayesha's Status	Match	Action Required
Stage III/IV epithelial ovarian	Stage IVB HGSOC	âœ… PASS	None
HER2 IHC 3+/2+/1+	UNKNOWN	âš ï¸ GATE	Order HER2 IHC NOW
BRCA wildtype	Germline negative	âœ… PASS	None
Completed platinum + bev frontline	Treatment-naive (will complete)	âœ… PASS	Complete SOC first
Local HRD or BRCA test	BRCA done, HRD pending	âš ï¸ PENDING	Await MyChoice results (Ordered?)
No PARP eligibility	TBD (depends on HRD)	âš ï¸ TBD	If HRD â‰¥42, NOT eligible (will get PARP SOC)
Adequate tumor tissue	Has tissue block	âœ… PASS	None
No ILD/pneumonitis history	No history	âœ… PASS	None
No active bowel obstruction	No obstruction	âœ… PASS	None
NYC site available	Mount Sinai recruiting	âœ… PASS	None

START: Ayesha completes carboplatin + paclitaxel + bevacizumab (L1)
  â”‚
  â”œâ”€â†’ HER2 IHC Test (ORDER NOW from biopsy tissue)
  â”‚    â”‚
  â”‚    â”œâ”€â†’ HER2 IHC 3+/2+/1+ (ANY EXPRESSION)?
  â”‚    â”‚    â”‚
  â”‚    â”‚    â”œâ”€â†’ YES â†’ Check HRD status
  â”‚    â”‚    â”‚    â”‚
  â”‚    â”‚    â”‚    â”œâ”€â†’ HRD â‰¥42 (HRD-high)?
  â”‚    â”‚    â”‚    â”‚    â”‚
  â”‚    â”‚    â”‚    â”‚    â”œâ”€â†’ YES â†’ **NOT ELIGIBLE** (will receive PARP maintenance per SOC)
  â”‚    â”‚    â”‚    â”‚    â”‚         [UNLESS contraindication to PARP exists]
  â”‚    â”‚    â”‚    â”‚    â”‚
  â”‚    â”‚    â”‚    â”‚    â””â”€â†’ NO (HRD <42 or negative) â†’ **ELIGIBLE FOR TRIAL!**
  â”‚    â”‚    â”‚    â”‚                                     â”‚
  â”‚    â”‚    â”‚    â”‚                                     â””â”€â†’ Randomize:
  â”‚    â”‚    â”‚    â”‚                                          â€¢ Arm A: T-DXd + bevacizumab (experimental)
  â”‚    â”‚    â”‚    â”‚                                          â€¢ Arm B: Bevacizumab alone (control)
  â”‚    â”‚    â”‚    â”‚
  â”‚    â”‚    â”‚    â””â”€â†’ HRD test pending â†’ Monitor results, proceed if <42
  â”‚    â”‚    â”‚
  â”‚    â”‚    â””â”€â†’ NO (HER2 IHC 0) â†’ **NOT ELIGIBLE** (bevacizumab maintenance only)
  â”‚    â”‚
  â”‚    â””â”€â†’ Test failed/insufficient tissue â†’ Repeat biopsy or alternative trial
  â”‚
  â””â”€â†’ END: Proceed with appropriate maintenance strategy
START: Ayesha completes carboplatin + paclitaxel + bevacizumab (L1)
  â”‚
  â”œâ”€â†’ HER2 IHC Test (ORDER NOW from biopsy tissue)
  â”‚    â”‚
  â”‚    â”œâ”€â†’ HER2 IHC 3+/2+/1+ (ANY EXPRESSION)? 
  â”‚    â”‚    â”‚
  â”‚    â”‚    â”œâ”€â†’ YES â†’ Check HRD status
  â”‚    â”‚    â”‚    â”‚
  â”‚    â”‚    â”‚    â”œâ”€â†’ HRD â‰¥42 (HRD-high)?
  â”‚    â”‚    â”‚    â”‚    â”‚
  â”‚    â”‚    â”‚    â”‚    â”œâ”€â†’ YES â†’ **NOT ELIGIBLE** (will receive PARP maintenance per SOC)
  â”‚    â”‚    â”‚    â”‚    â”‚         [UNLESS contraindication to PARP exists]
  â”‚    â”‚    â”‚    â”‚    â”‚
  â”‚    â”‚    â”‚    â”‚    â””â”€â†’ NO (HRD <42 or negative) â†’ **ELIGIBLE FOR TRIAL!**
  â”‚    â”‚    â”‚    â”‚                                     â”‚
  â”‚    â”‚    â”‚    â”‚                                     â””â”€â†’ Randomize:
  â”‚    â”‚    â”‚    â”‚                                          â€¢ Arm A: T-DXd + bevacizumab (experimental)
  â”‚    â”‚    â”‚    â”‚                                          â€¢ Arm B: Bevacizumab alone (control)
  â”‚    â”‚    â”‚    â”‚
  â”‚    â”‚    â”‚    â””â”€â†’ HRD test pending â†’ Monitor results, proceed if <42
  â”‚    â”‚    â”‚
  â”‚    â”‚    â””â”€â†’ NO (HER2 IHC 0) â†’ **NOT ELIGIBLE** (bevacizumab maintenance only)
  â”‚    â”‚
  â”‚    â””â”€â†’ Test failed/insufficient tissue â†’ Repeat biopsy or alternative trial
  â”‚
  â””â”€â†’ END: Proceed with appropriate maintenance strategðŸ’¡ STRATEGIC IMPLICATIODECISION FLOWCHART FOR ONCOLOGIST:

ðŸš¨ CRITICAL DECISION TREE FOR AYESHA

START: Ayesha completes carboplatin + paclitaxel + bevacizumab (L1) 
  â”‚
  â”œâ”€â†’ HER2 IHC Test (ORDER NOW from biopsy tissue)
  â”‚    â”‚
  â”‚    â”œâ”€â†’ HER2 IHC 3+/2+/1+ (ANY EXPRESSION)?
  â”‚    â”‚    â”‚
  â”‚    â”‚    â”œâ”€â†’ YES â†’ Check HRD status
  â”‚    â”‚    â”‚    â”‚
  â”‚    â”‚    â”‚    â”œâ”€â†’ HRD â‰¥42 (HRD-high)?
  â”‚    â”‚    â”‚    â”‚    â”‚
  â”‚    â”‚    â”‚    â”‚    â”œâ”€â†’ YES â†’ **NOT ELIGIBLE** (will receive PARP maintenance per SOC)
  â”‚    â”‚    â”‚    â”‚    â”‚         [UNLESS contraindication to PARP exists]
  â”‚    â”‚    â”‚    â”‚    â”‚
  â”‚    â”‚    â”‚    â”‚    â””â”€â†’ NO (HRD <42 or negative) â†’ **ELIGIBLE FOR TRIAL!**
  â”‚    â”‚    â”‚    â”‚                                     â”‚
  â”‚    â”‚    â”‚    â”‚                                     â””â”€â†’ Randomize:
  â”‚    â”‚    â”‚    â”‚                                          â€¢ Arm A: T-DXd + bevacizumab (experimental)
  â”‚    â”‚    â”‚    â”‚                                          â€¢ Arm B: Bevacizumab alone (control)
  â”‚    â”‚    â”‚    â”‚
  â”‚    â”‚    â”‚    â””â”€â†’ HRD test pending â†’ Monitor results, proceed if <42
  â”‚    â”‚    â”‚
  â”‚    â”‚    â””â”€â†’ NO (HER2 IHC 0) â†’ **NOT ELIGIBLE** (bevacizumab maintenance only)
  â”‚    â”‚
  â”‚    â””â”€â†’ Test failed/insufficient tissue â†’ Repeat biopsy or alternative trial
  â”‚
  â””â”€â†’ END: Proceed with appropriate maintenance strategy

ðŸ’¡ STRATEGIC IMPLICATIONS
Best-Case Scenario (HER2+ AND HRD-negative):
âœ… Ayesha enrolls in DESTINY-Ovarian01 at Mount Sinai
âœ… 50% chance of experimental arm (T-DXd + bev)
âœ… Even control arm (bev alone) is SOC
âœ… If randomized to T-DXd arm â†’ Access to cutting-edge ADC therapy
âœ… Close monitoring, free drug, expert care at Mount Sinai
Most Likely Scenario (HER2+ AND HRD â‰¥42):
âš ï¸ NOT eligible for trial (will receive PARP maintenance per SOC)
âœ… PARP maintenance is EXCELLENT for HRD-high patients (olaparib/niraparib)
âœ… This is actually GOOD news (HRD-high = better prognosis, proven therapy)
Challenge Scenario (HER2 IHC 0):
âŒ NOT eligible for this trial
âœ… Falls back to bevacizumab maintenance (standard SOC)
âœ… Pursue alternative trials (ATR/CHK1 combos, other mechanisms)
DECISION FLOWCHART FOR ONCOLOGIST:
Week 1: Complete platinum + paclitaxel + bevacizumab (Cycle 6)
  â”‚
  â”œâ”€â†’ Order HER2 IHC (3-5 days)
  â”‚    â””â”€â†’ Results: HER2 3+/2+/1+ or 0?
  â”‚
  â”œâ”€â†’ Await HRD results (7-10 days)
  â”‚    â””â”€â†’ Results: HRD â‰¥42 or <42?
  â”‚
  â””â”€â†’ Week 2-3: Eligibility determination
       â”‚
       â”œâ”€â†’ HER2+ AND HRD <42 â†’ **ENROLL IN NCT06819007** (Mount Sinai)
       â”‚
       â”œâ”€â†’ HER2+ AND HRD â‰¥42 â†’ **PARP MAINTENANCE** (olaparib/niraparib)
       â”‚                        [Unless PARP contraindication exists]
       â”‚
       â””â”€â†’ HER2 IHC 0 â†’ **BEVACIZUMAB MAINTENANCE** (standard SOC)
                        [Pursue alternative trials]

âš”ï¸  FINAL RECOMMENDATION
THIS IS A TOP-TIER TRIAL FOR AK (1 in 700) ðŸ”¥
Priority Rank: #1 (if HER2+ and HRD-negative/low)Action Plan:
âœ… Order HER2 IHC THIS WEEK (3-5 day turnaround)
âœ… Monitor HRD results (already ordered, 7-10 days)
âœ… Pre-screen with Mount Sinai (get on coordinator's radar)
âœ… Decision at Week 2: Enroll if HER2+ AND (HRD <42 OR PARP-ineligible)
Expected Timeline:
Week 1: Complete L1 chemo (cycle 6)
Week 2: HER2/HRD results available
Week 3: Enroll in trial (if eligible) or proceed with SOC maintenance
Probability Ayesha Is Eligible:
HER2+ prevalence in ovarian: 40-60% â†’ 50% chance
HRD-negative (given germline BRCA-negative): 50-70% â†’ 60% chance
Combined probability: ~30-35% she's eligible
Value Proposition:
If eligible â†’ Access to breakthrough ADC therapy (T-DXd)
If not eligible (HRD-high) â†’ Gets proven PARP therapy (still excellent)
WIN-WIN SCENARIO
